Quinze-Vingts National Ophthalmology Hospital — Clinical Trial Site

38 Registered trials

16 Currently recruiting

Organisation

Quinze-Vingts National Ophthalmology Hospital

Location

Paris, France

Identifier

ORG-100009504

Address

28 Rue De Charenton, 75012, France

Departments

1509:Medecine Interne
Center for Rare Disease
Centre d ’Investigation Clinique 1423
Centre de maladies rares CHNO des Quinze Vingt
Centre National de Reference Maladies Rares REFERET
CIC 1423
Clinical Investigation Center
Electrophysiology unit
Internal medicine
Internal Medicine Department
Medecine Interne
Neurology
Oncopole
Ophtalmogie
ophtalmologie
Ophtalmology
Ophtalmology – Service Pr Paques
Ophtalomogy
Ophthalmology
Service d'onco-ophtalmologie
Service d’ophtalmologie
Service de Médecine Interne

Clinical trials at this site (38)

Search interface

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B Ended

2024-513500-34-00 Usher's syndrome 4 2015-11-09
Evaluation of the effects of bosentan in the management of patients in the acute phase of acute anterior ischemic optic neuropathy. Ended

2024-518345-21-00 early stage of acute non-arteritic anterior ischemic op 5 2015-07-31
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular Degeneration Ended

2024-513501-31-00 Congenital, hereditary and neonatal diseases 4 2013-05-30
Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended

2024-519977-20-00 Acute Anterior Ischemic Optic Neuropathy associated wit 4 2025-01-27
A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended

2023-507563-19-00 Thyroid eye disease 5 2024-11-05
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509198-22-00 Thyroid Eye Disease (TED) 5 2024-10-21
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended

2023-506707-25-00 Choroidal neovascularization secondary to pathologic my 5 2024-04-09
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended

2022-502174-16-00 Macular edema secondary to retinal vein occlusion 5 2023-09-13
Phase 3 Study of Tinlarebant in the Treatment in Adolescent Stargardt Subjects Ended

2024-513483-26-00 Stargardt Disease 5 2022-11-28
N/A Ended

2024-515090-96-00 Thyroid Eye Disease 11 2022-05-10
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended

2023-508571-37-00 Geographic atrophy (GA) secondary to Age-related Macula 4 2022-04-29
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended

2024-512945-18-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2021-11-30
Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melano… Ended

2024-513746-11-00 Patient with large choroid melanoma 7 mm thick and/or m 5 2017-06-08